3.77

2.08% -0.08

After Hours: 3.80 0.03 +0.80%

Aileron Therapeutics Inc (ALRN)

Overview News Price History Financials Discussions Forecast Stock Split

Aileron Therapeutics Inc stock is currently priced at $3.77, with a 24-hour trading volume of 19,489. It has seen a -2.08% decreased in the last 24 hours and a -11.29% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $3.87 pivot point. If it approaches the $3.73 support level, significant changes may occur.

Previous Close:

$3.85

Open:

$3.85

24h Volume:

19,489

Market Cap:

$79.71M

Revenue:

Net Income/Loss:

$-12.94M

P/E Ratio:

-1.3275

EPS:

-2.84

Net Cash Flow:

$-13.83M

1W Performance:

-1.31%

1M Performance:

-11.29%

6M Performance:

+96.35%

1Y Performance:

+167.38%

1D Range:

$3.70

$3.85

52W Range:

$1.01

$7.42

Aileron Therapeutics Inc Stock (ALRN) Company Profile

Name

Aileron Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

617 995 0900

Address

285 Summer Street, Suite 101, Boston, MA

Employee

Twitter

@Aileron_org

Next Earnings Date

2024-05-20

Latest SEC Filings

ALRN's Discussions on Twitter

Aileron Therapeutics Inc Stock (ALRN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-24-17	Initiated	BofA/Merrill	Buy
Jul-24-17	Initiated	Jefferies	Buy
Jul-24-17	Initiated	William Blair	Outperform

Aileron Therapeutics Inc Stock (ALRN) Latest News

Aileron Therapeutics Announces New Interim CFO Appointment - TipRanks.com - TipRanks

TipRanks

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

GlobeNewswire

Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

GlobeNewswire Inc.

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Sees Significant Growth in Short Interest - MarketBeat

MarketBeat

Aileron Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview - XM

New Strong Sell Stocks for November 24th - Yahoo Canada Shine On

Yahoo Canada Shine On

Aileron Therapeutics Inc Stock (ALRN) Financials Data

Aileron Therapeutics Inc (ALRN) Net Income 2024

ALRN net income (TTM) was -$12.94 million for the quarter ending September 30, 2023, a +56.26% increase year-over-year.

Aileron Therapeutics Inc (ALRN) Cash Flow 2024

ALRN recorded a free cash flow (TTM) of -$13.83 million for the quarter ending September 30, 2023, a +48.24% increase year-over-year.

Aileron Therapeutics Inc (ALRN) Earnings per Share 2024

ALRN earnings per share (TTM) was -$2.84 for the quarter ending September 30, 2023, a +56.37% growth year-over-year.

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.